Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
Located at 325 Hymus Blvd. in Pointe-Claire, the project is the latest in a series of Lib developments to open in Quebec, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results